DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

Phase 1

Active, not recruiting

Conditions: Non-small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Vorinostat
Drug: Pembrolizumab

First Posted Date: 2015-12-22

Last Posted Date: 2025-05-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 120

Registration Number: NCT02638090

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Phase 2

Completed

Conditions: Cholangiocarcinoma
Gastrointestinal Tumor
Biliary Carcinoma
Gall Bladder Carcinoma

Interventions: Drug: Cisplatin
Drug: Gemcitabine
Drug: Copanlisib

First Posted Date: 2015-12-16

Last Posted Date: 2021-08-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 24

Registration Number: NCT02631590

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Smoking-cessation: A Spanish-Language Clinical Trial

Not Applicable

Completed

Conditions: Tobacco Dependence
Smoking Cessation

Interventions: Behavioral: Stop Smoking for Good Intervention in Spanish (SS-SP)
Behavioral: Usual care (UC)

First Posted Date: 2015-11-20

Last Posted Date: 2022-01-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 42

Registration Number: NCT02611076

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Phase 2

Completed

Conditions: Malignant Pleural Mesothelioma
Mesothelioma

Interventions: Drug: Cisplatin
Drug: Methotrexate
Drug: Gemcitabine
Other: Lung Cancer Symptom Scale for Mesothelioma Questionnaire

First Posted Date: 2015-11-20

Last Posted Date: 2025-05-08

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 34

Registration Number: NCT02611037

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention

Not Applicable

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Other: Therapy for Targeted Therapy-related Fatigue (TTF)
Other: Wait-List Control Condition (WLC)

First Posted Date: 2015-10-30

Last Posted Date: 2021-11-16

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 48

Registration Number: NCT02592447

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

Phase 2

Completed

Conditions: Graft Versus Host Disease
GVHD

Interventions: Drug: Panobinostat
Drug: Sirolimus
Drug: Tacrolimus

First Posted Date: 2015-10-27

Last Posted Date: 2021-07-21

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 42

Registration Number: NCT02588339

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer - Male
Breast Cancer
Breast Cancer - Female

Interventions: Drug: Tamoxifen
Drug: Ribociclib
Drug: Goserelin

First Posted Date: 2015-10-26

Last Posted Date: 2022-01-21

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 7

Registration Number: NCT02586675

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Phase 2

Completed

Conditions: Carcinoid Tumors
Pancreatic NET

Interventions: Drug: Ibrutinib

First Posted Date: 2015-10-14

Last Posted Date: 2020-09-11

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT02575300

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Radiation: Stereotactic Body Radiation Therapy (SBRT)
Procedure: Prostatectomy
Other: Quality of Life Questionnaires

First Posted Date: 2015-10-08

Last Posted Date: 2023-01-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 7

Registration Number: NCT02572284

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: AZD1775

First Posted Date: 2015-07-31

Last Posted Date: 2025-04-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 42

Registration Number: NCT02513563

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy